// App-Quantinova.ai

TPS1099 : A co-clinical phase II trial of carboplatin and docetaxel as neoadjuvant treatment for triple negative breast cancer with genomic discovery analysis.

Researchers

Presenter

  • Foluso Olabisi Ademuyiwa

Principal Investigators

  • Shunqiang Li

  • Tracy Skinner

  • Jason Hoshower

  • Jingqin Luo

  • Cynthia X. Ma

  • Katherine N. Weilbaecher

  • Michael Naughton

  • Leonel Fernando Hernandez-Aya

  • Elaine R. Mardis

  • Matthew James Ellis

Medical Centers

  • Washington University School of Medicine, St. Louis, MO

  • Siteman Cancer Center, Washington University, Saint Louis, MO

  • Washington University School of Medicine, St. Louis, MO

  • Division of Oncology, Washington University School of Medicine, St. Louis, MO

  • The Genome Institute at Washington University in St. Louis, St. Louis, MO

  • Lester and Sue Smith Breast Center, Baylor Clinic, Baylor College of Medicine, Houston, TX

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Triple-negative breast cancer

  • Breast cancer

Biomarkers

  • N/A

Drug/Treatment

  • Carboplatin

  • Docetaxel

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • NCT02124902

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved